[HTML][HTML] Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic …
K Fizazi, R Jones, S Oudard, E Efstathiou… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2015•ncbi.nlm.nih.gov
Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus
Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant
Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI
Homepage Main Content Main Navigation Search PMC Full-Text Archive Search in PMC
Advanced Search User Guide Journal List J Clin Oncol PMC4879718 Other Formats …
Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant
Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI
Homepage Main Content Main Navigation Search PMC Full-Text Archive Search in PMC
Advanced Search User Guide Journal List J Clin Oncol PMC4879718 Other Formats …
Abstract
Purpose
Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17, 20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy.
ncbi.nlm.nih.gov